

Joint Working EXECUTIVE SUMMARY

Published on www.astrazeneca.co.uk

Joint Working between AstraZeneca UK Ltd and The Newcastle upon Tyne Hospitals NHS Foundation Trust

Document Number 307-1-ES

Date of Preparation Nov 2025

Project title	CLEAR-SC Newcastle
Aims and Objectives	Optimise the identification and management of Severe Asthma patients Increase number of suspected Severe Asthma patient reviews Increase uptake / initiation of biologics where appropriate to do so Reduction in OCS usage in patients identified Improvement in symptoms / ACQ score) in all patients identified Accelerating SA patient pathway timelines – time to MDT / appropriate treatment.
Anticipated benefits	It is expected that this project will support the following groups in the following ways: Patient: Optimised Treatment: Appropriately being identified as a patient who may benefit from alternative treatment options for severe asthma. Appropriate initiation and optimisation of medicines by Specialists in-line with local and national guidelines Fewer Hospital Visits: Early, customised interventions will likely lead to a reduction in non-elective admissions and readmissions, easing the burden on patients. Improved Care Quality: Patients may experience significant improvements in the quality of care they receive, potentially enhancing their quality of life. NHS: Decreased Waiting Times: The project aims to reduce waiting times for specialist consultations, improving patient flow. Improved Care Quality: The overall quality of care for patients with severe asthma will be enhanced. Reduced Unplanned Admissions: In the longer term, the project is expected to improve patient flow and reduce the total number of unplanned admissions and inpatient bed days. AstraZeneca: Align with Medical Mission: The project supports AstraZeneca's strategy to improve the lives of asthma patients, including those with severe asthma, by promoting early identification and optimal treatment. Optimised Medicine Use: The initiative supports the optimisation of medicines for the treatment of severe asthma. While the prescribing of AstraZeneca medicines may increase, the decision to prescribe will remain clinician-led in accordance with local protocols and guidelines. Share Best Practices: A successful project with demonstrable outcomes will allow AstraZeneca to share best practices across the UK healthcare system. Enhanced Reputation: The project is anticipated to

	improve AstraZeneca's corporate reputation and trust amongst the NHS and patients
Timeline	The project will commence on the Dec 2025 and will continue for a duration of 12 months.
References	[References]